HROW Harrow Health Inc.

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Conference Call Details: 
Date:Tuesday, August 10, 2021
Time:4:45 p.m. Eastern time
Participant Dial-in:1-833-953-2434 (U.S.)

1-412-317-5763 (International)
Replay Dial-in (Passcode 10157937):

(telephonic replay through August 17, 2021)
1-877-344-7529 (U.S.)

1-412-317-0088 (International)
Webcast: (online replay through November 10, 2021)harrowinc.com

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contact:

Jamie Webb, Director of Communications and Investor Relations

[email protected]

615-733-4737

 



EN
26/07/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conferen...

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida. The presentation will be and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, Inc. (Nasdaq: HROW) is a leading p...

 PRESS RELEASE

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE®...

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial evaluating TRIESENCE (preservative-free triamcinolone acetonide injectable suspension) 40 mg/mL for the treatment of ...

 PRESS RELEASE

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Fina...

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Ca...

 PRESS RELEASE

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results Af...

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026 NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the...

 PRESS RELEASE

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaPack kits expand access to F...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch